Alport syndrome
Alport · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Hereditary type IV collagen disorder (most commonly X-linked COL4A5) causing progressive haematuric nephritis with sensorineural hearing loss and ocular abnormalities. Early RAAS blockade slows progression toward end-stage kidney disease.
Red flags
- Rapidly rising proteinuria or declining eGFR
- Progressive hearing loss
- Ocular changes (lenticonus, maculopathy)
- Family history of early kidney failure
- Post-transplant anti-GBM-like nephritis (rare)
Assessment
Differential diagnosis
- Thin basement membrane nephropathy
- IgA nephropathy
- Other hereditary nephritis
- Acquired glomerulonephritis
- Fabry disease
- Autosomal forms of Alport (COL4A3/COL4A4)
Investigations
- Urinalysis and urine ACR/PCR (persistent haematuria +/- proteinuria)
- Renal function trend
- Audiometry for sensorineural hearing loss
- Ophthalmology (anterior lenticonus, dot-and-fleck retinopathy)
- Genetic testing (COL4A3/4/5) — now preferred to biopsy
- Family history/pedigree; kidney biopsy with electron microscopy if genetics unavailable
Management
- Suspect in persistent glomerular haematuria with family history of kidney failure and/or hearing loss
- Confirm with genetic testing of COL4A3/COL4A4/COL4A5 (first-line); reserve biopsy with EM (basket-weave GBM) for uncertain cases
- Establish inheritance pattern and counsel family; offer cascade screening
- Quantify proteinuria and monitor eGFR to assess progression risk
- Start ACE inhibitor (or ARB) early, even with microalbuminuria, to delay progression
- Optimise blood pressure to a low target
- Arrange baseline and periodic audiology and ophthalmology review
- Avoid nephrotoxins and manage cardiovascular risk
- Discuss SGLT2 inhibitor as adjunct in proteinuric CKD where appropriate
- Plan for renal replacement/transplant as CKD advances (transplant generally does well; rare anti-GBM-like disease post-transplant)
- Provide genetic counselling for reproductive decisions
- Monitor renal function, proteinuria, BP, hearing and eyes at regular intervals
Drugs & doses
Ramipril 2.5-10 mg PO daily (start early even with microalbuminuria)
Losartan 50-100 mg PO daily (if ACEi not tolerated)
Dapagliflozin 10 mg PO once daily (adjunct for proteinuric CKD)
Amlodipine 5-10 mg PO daily (additional BP control)
Disposition
Nephrology clinic with genetics, audiology and ophthalmology input. Family screening. Transplant assessment as CKD advances.
Complications & pitfalls
- Progressive CKD and end-stage kidney disease
- Sensorineural deafness
- Ocular complications and visual impairment
- Rare post-transplant anti-GBM nephritis
- Aortic/vascular involvement in some genotypes
Exam pearls
- Early RAAS blockade (even microalbuminuria) delays kidney failure — the key intervention
- Genetic testing has largely replaced biopsy for diagnosis
- Think Alport in haematuria plus deafness or a strong family history
- Carrier females (X-linked) can still progress and need monitoring
- Thin basement membrane disease and autosomal Alport overlap genetically
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.